	US 12,466,857 B2
	Triple-helical polypeptides lacking binding affinity for the Fc domain of immunoglobulin and uses thereof
Erik Fiedler, Halle/Saale (DE); Ulrich Haupts, Halle/Saale (DE); and Madlen Zwarg, Halle/Saale (DE)
Assigned to Navigo Proteins GmbH, Halle/Saale (DE)
Appl. No. 17/292,212
Filed by Navigo Proteins GmbH, Halle/Saale (DE)
PCT Filed Nov. 12, 2019, PCT No. PCT/EP2019/081078 § 371(c)(1), (2) Date May 7, 2021, PCT Pub. No. WO2020/099442, PCT Pub. Date May 22, 2020.
Claims priority of application No. 18205679 (EP), filed on Nov. 12, 2018; and application No. 19167107 (EP), filed on Apr. 3, 2019.
Prior Publication US 2022/0073564 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/00 (2006.01)

CPC C07K 14/001 (2013.01) [C07K 2319/00 (2013.01)]

8 Claims

1. A polypeptide having at least 90% identity to any one of SEQ ID NOs: 1-15 and 23-30, wherein the polypeptide comprises:

a) an acidic amino acid selected from aspartic acid (D) and glutamic acid (E) at the position corresponding to position 13 of SEQ ID NO: 1-15 and 23-30; and

b) a basic amino acid selected from any one of arginine (R), lysine (K), and histidine (H) at the position corresponding to position 31 of SEQ ID NOs: 1-15 and 23-30,

and further wherein the polypeptide has no detectable binding affinity for the Fc domain of immunoglobulin as determined by Surface Plasmon Resonance (SPR).